Liver Transplant for Liver Cancer: 2022 Liver Transplant Virtual CME Series

Penn Medicine's Peter L. Abt, MD, Surgical Director of the Liver Transplant Program, and Maarouf A. Hoteit, MD, Medical Director of the Liver Transplant Program and Director of the Liver Tumor Clinic, present session two of this year's Liver Transplant Virtual CME Series to share their perspectives on liver transplantation as an ideal treatment for early stage nonresectable hepatocellular carcinoma (HCC), review local regional therapy for down-staging of HCC tumors exceeding standard criteria for transplant, and offer insight on the selection criteria and treatment protocols for liver transplantation in cholangiocarcinoma, formerly an absolute contraindication to transplantation.

#PennMedicine #LiverTransplant #LiverCancer

[khaliddurrani]

Milan as well as BCLC are restrictive as regards curative treatment of HCC. Milan relies on morphology alone whereas BCLC is based on patient characteristics along with morphology. Now that we have learned that Biology of the tumor is another major determinant of overall outcome, more and more emphasis is placed on it in planning of treatment ie response to neoadj loci-regional therapies as down-staging protocols and immunotherapy in future.